BLOCKING Act of 2019
Latest action · May 2, 2019 Placed on the Union Calendar, Calendar No. 24.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 31, 2019
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019 or the BLOCKING Act of 2019
This bill modifies provisions related to market exclusivity for a generic drug.
Currently, the Food and Drug Administration (FDA) awards 180 days of exclusivity on the market to a first applicant to file a qualifying application for market approval of a generic drug. Generally, this exclusivity period begins upon a first applicant's commercial marketing of the drug.
The bill authorizes the FDA to approve a subsequent generic drug application prior to a first applicant's first date of commercial marketing if (1) the subsequent application is ready for full approval, (2) a first applicant's application has been pending for at least 30 months, and (3) the approval of a first applicant's application is not precluded by patent infringement claims asserted against that first applicant.
Cosponsors 16
Members who signed on, in the order they did. Signatures ran from Jan 31, 2019 to May 1, 2019; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-GA | Earl L. "Buddy" Carter | Original | Jan 31, 2019 |
| D-MN | Angie Craig | Mar 25, 2019 | |
| D-CA | Anna G. Eshoo | Mar 26, 2019 | |
| D-MI | Debbie Dingell | Mar 26, 2019 | |
| D-NJ | Frank Pallone, Jr. | Mar 26, 2019 | |
| D-CA | Raul Ruiz | Mar 26, 2019 | |
| D-IL | Bobby L. Rush | Mar 27, 2019 | |
| D-CA | Doris O. Matsui | Mar 27, 2019 | |
| D-MA | Joseph P. Kennedy III | Mar 27, 2019 | |
| D-NJ | Jefferson Van Drew | Mar 29, 2019 | |
| D-NY | Yvette D. Clarke | Apr 2, 2019 | |
| R-OR | Greg Walden | Apr 8, 2019 | |
| D-IL | Janice D. Schakowsky | Apr 8, 2019 | |
| D-UT | Ben McAdams | Apr 10, 2019 | |
| D-FL | Debbie Mucarsel-Powell | Apr 29, 2019 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 31, 2019Markup Apr 3, 2019Reported May 2, 2019 |
| Health Subcommittee | Referred Feb 2, 2019Markup Mar 27, 2019Reported Mar 27, 2019 |
Actions 9
Everything that happened, newest first.
- May 2, 2019Reported by the Committee on Energy and Commerce. H. Rept. 116-46.
- May 2, 2019Placed on the Union Calendar, Calendar No. 24.
- Apr 3, 2019Committee Consideration and Mark-up Session Held.
- Apr 3, 2019Ordered to be Reported by Voice Vote.
- Mar 27, 2019Subcommittee Consideration and Mark-up Session Held.
In the Congressional Record 2
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| House | Debate and remarks H10118 | Earl L. "Buddy" Carter R-GA | Dec 11, 2019 |
| House | Debate and remarks H3429 | Ben McAdams D-UT | May 2, 2019 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Committee report
Congressional Budget Office cost estimate
- Apr 30, 2019H.R. 938, Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019As ordered reported by the House Committee on Energy and Commerce on April 3, 2019
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 165, no. 20, January 31, 2019, page H1342.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 116-17 | LOWERING THE COST OF PRESCRIPTION DRUGS: REDUCING BARRIERS TO MARKET COMPETITION252 pages | Energy and Commerce Committee | Mar 13, 2019 |
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 3
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 19 | Lower Costs, More Cures Act of 2019 | Related bill | Dec 19, 2019 |
| HR 987 | Strengthening Health Care and Lowering Prescription Drug Costs Act | Related bill | May 20, 2019 |
| HR 2700 | Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act | Related bill | Jun 26, 2019 |
Titles 5
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
- Short Title(s) as Introduced
- BLOCKING Act of 2019
- Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019
- Short Title(s) as Reported to House
- BLOCKING Act of 2019
- Bringing Low-cost Options and Competition while Keeping Incentives for New Generics Act of 2019
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 2
Each version as it was printed, newest first.
- May 2, 2019Reported in House
- Jan 31, 2019Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.